lifestyle.hubspotes.com

Author: Theriva Biologics, Inc.

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

May 7, 2026
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

April 17, 2026
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

March 23, 2026
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

March 12, 2026
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

February 18, 2026
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

February 3, 2026